Two receptors, two levers on growth hormone
Growth hormone (GH) is released from the pituitary gland in pulses, and the body controls those pulses with more than one signal. Growth-hormone-releasing hormone (GHRH) tells the pituitary to release GH, while somatostatin acts as the brake that suppresses it. Separately, the stomach hormone ghrelin acts on the GH-secretagogue receptor (GHS-R) to further stimulate GH release.
CJC-1295 is a synthetic analog of GHRH, so it works on the GHRH receptor to increase the amount of GH released in a pulse. Ipamorelin is a synthetic ghrelin-receptor agonist that mimics ghrelin at the GHS-R. Because these are two distinct receptors driving the same output through different upstream routes, studying them together is a way to probe whether their effects add up to more than the sum of the parts.
What each compound contributes
A GHRH analog such as CJC-1295 primarily raises the amplitude of the GH signal the pituitary is already trying to produce. It reinforces the natural instruction to secrete GH rather than overriding the system, which is why researchers describe it as working with the body's feedback loops instead of against them.
Ipamorelin contributes on the ghrelin side, and it is often described as selective. Older secretagogues such as GHRP-6 and GHRP-2 tend to also raise cortisol and prolactin and to stimulate appetite strongly. In studies, ipamorelin releases GH with comparatively little effect on cortisol and prolactin, which is the basis for calling it a cleaner GHS-R agonist.
Combining a GHRH analog with a ghrelin-receptor agonist is reported to be synergistic because each addresses a different part of the control system at once: one amplifies the release signal while the other adds independent stimulation and may reduce the somatostatin brake. The result described in research settings is a larger GH pulse than either alone tends to produce.
DAC versus no-DAC
CJC-1295 exists in two forms that behave very differently in time. The no-DAC version, also known as Mod GRF 1-29, is short-acting, with a half-life measured in roughly tens of minutes. It produces a brief, sharp rise in GH that resembles a natural pulse and then clears quickly.
DAC stands for Drug Affinity Complex, a group added to the peptide that binds to serum albumin in the bloodstream. That binding protects the molecule from rapid breakdown and extends its half-life to a matter of days. Instead of a discrete pulse, the DAC version produces a prolonged elevation of GH and IGF-1. The trade-off researchers weigh is pulse fidelity versus convenience: no-DAC better mimics physiologic pulsing, while DAC sustains levels with far less frequent exposure.
Timing rationale in research
Timing is a recurring theme because GH secretion is naturally shaped by sleep, fasting, and blood sugar. The body's largest GH pulses tend to occur during deep sleep, and secretion is generally higher in a fasted state. This is why research designs often examine short-acting secretagogues around sleep or away from meals to align an induced pulse with the body's own rhythm.
Food, and specifically the insulin and blood-glucose rise after eating, tends to blunt GH release. High circulating glucose and elevated somatostatin both work against a GH pulse, so exposures studied close to a large carbohydrate load may produce a smaller response.
Safety and regulatory context
Reported effects of GH secretagogues in research include water retention, tingling or numbness in the extremities, joint discomfort, and increased hunger, the last most associated with ghrelin-receptor activity. Because these compounds raise GH and downstream IGF-1, effects on insulin sensitivity and blood glucose are a documented area of study.
Regulatory status is the crucial caveat. CJC-1295 and ipamorelin are not FDA-approved drugs, and the long-acting DAC version never advanced to approval; they are sold and handled as research chemicals, not medicines. The closest approved comparator is tesamorelin, approved only for HIV-associated lipodystrophy. This guide is educational and does not describe human use.